PER® Miami Breast Cancer Conference | Conference

Applying RxPONDER to Clinical Practice

March 30th 2021

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

March 22nd 2021

Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel.

Are New Ways to Reduce Positive Margins in Breast Cancer Hope or Hype?

March 10th 2021

There are a number of strategies to reduce margin positivity, particularly after partial mastectomy, but the relative effectiveness of each varies, as do the data that support their use.

PARP Inhibitors Remain Key Players in Metastatic Breast Cancer

March 8th 2021

Olaparib and talazoparib failed to demonstrate statistically significant improvements in overall survival compared with chemotherapy in pretreated patients with BRCA1/2-mutant metastatic HER2-negative breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control

An Autopsy of Breast Cancer Management Amidst the COVID-19 Pandemic

March 7th 2021

One year into the COVID-19 pandemic has allowed for some reflection on the different evolutions that the oncology community went through in response to the many challenges posed by the virus.

Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging

March 7th 2021

Stimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.

Genomics, AI, and Demography Will Remake Cancer Care by 2030

March 7th 2021

A wave of approvals and a rapidly evolving treatment landscape could make the next decade a watershed period in breast cancer care.

Addressing Treatment Disparities Among Younger Women with Breast Cancer

March 6th 2021

Even in 2021, disparities in outcomes of younger women with breast cancer vs their older counterparts remain; addressing behavioral issues and psychological concerns in this population could vastly improve their quality of life, treatment adherence, and ultimately, survival.

The Marshall Family Faces Off Against TNBC

March 6th 2021

Off Our Chests: A Candid Tour Through the World of Cancer is a memoir that dives into Liza Marshall’s breast cancer journey.

Neoadjuvant Checkpoint Inhibition Shows Promise in TNBC, But Is Not Ready for Clinical Use

March 6th 2021

Although phase 3 data suggest that the addition of checkpoint inhibitors to neoadjuvant chemotherapy could improve pathologic complete response rates for patients with early-stage triple-negative breast cancer, immature data and the risk of long-term toxicity indicate that the therapy is not ready for primetime